TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Fusen Pharmaceutical Co., Ltd. ( (HK:1652) ) just unveiled an announcement.
Fusen Pharmaceutical Co., Ltd. has announced significant changes in its board composition effective from September 30, 2025. Mr. Sze Wing Chun has resigned as an independent non-executive director and chairman of the Audit Committee, while Mr. Yu Ho Ming has been appointed as an independent non-executive director and a member of the Audit Committee. Additionally, Mr. Lee Kwok Tung Louis has been appointed as the chairman of the Audit Committee. These changes are expected to bring new expertise and perspectives to the company’s governance, potentially impacting its strategic direction and stakeholder relations.
The most recent analyst rating on (HK:1652) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on Fusen Pharmaceutical Co., Ltd. stock, see the HK:1652 Stock Forecast page.
More about Fusen Pharmaceutical Co., Ltd.
Fusen Pharmaceutical Co., Ltd. is a company incorporated in the Cayman Islands, operating in the pharmaceutical industry. The company, along with its subsidiaries, focuses on the development and distribution of pharmaceutical products.
Average Trading Volume: 2,177,365
Technical Sentiment Signal: Buy
Current Market Cap: HK$514.7M
See more data about 1652 stock on TipRanks’ Stock Analysis page.